1. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia 
Jing Wang, Qian Jiang, Lan-ping Xu, Xiao-Hui Zhang, Huan Chen, Ya-Zhen Qin, Guo-rui Ruan, Hao Jiang, Jin-song Jia, Ting Zhao, Kai- Yan Liu, Bin Jiang, Xiao-Jun Huang 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 4, Pages (April 2018)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Molecular response to TKIs plus chemotherapy for all patients and for patients with or without IKZF1 deletion.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Survival of the entire cohort by therapy. (A) Cumulative incidence of relapse. (B) Disease-free survival. (C) Overall survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Survival in low-, intermediate-, and high-risk patients by therapy. (A, D, and G) Cumulative incidence of relapse. (B, E, and H) Disease-free survival. (C, F, and I) Overall survival. (A-C) In the low-risk group 4-year CIR, DFS, and OS rates were 8.5% versus 7.7% (P = .671), 88.2% versus 83.9% (P = .426), and 96.6% versus 83.3% (P = .128), respectively, in the transplant versus the nontransplant group. (D-F) In the intermediate-risk group 4-year CIR, DFS, and OS rates were 23.6% versus 36.9% (P = .017), 62.4% versus 43.8% (P = .048), and 76.1% versus 47.7% (P = .037), respectively, in the transplant versus the nontransplant group. (G-I) In the high-risk group 4-year CIR, DFS, and OS rates were 37.5% versus 100.0% (P  < .001), 56.2% versus 0% (P  < .001), and 51.4% versus .8% (P = .001), respectively, in the transplant versus the nontransplant group.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions